探討矽氧烷基親水性高分子改質矽膠表面降低非特異性蛋白質吸附

Abstract

青光眼係指一種造成眼睛不可回復性損傷的疾病,此類疾病嚴重時往往會導 致失明。而眼內壓的升高被認為是造成青光眼的重要病因,因此在青光眼的治療 上多以降低眼內壓為目標。目前,使用青光眼引流裝置為近年來主要治療青光眼 之方法,因其可達到抑制青光眼病情之效果。然而,外科植入手術所產生的傷口 會導致人體之傷口修復機制啟動,蛋白質的貼附、纖維母細胞之沾黏與增生最終 使傷口纖維化,導致青光眼引流裝置無法達到應有之功效。因此本研究所使用之 青光眼引流裝置最主要材料-矽膠作為引流管基底,並設計了一個兩階段矽膠表 面改質方法:(一)首先挑選三種常見之親水性分子與矽氧烷基合成高分子後,(二) 再將此高分子接枝到矽膠上以降低非特異性蛋白質貼附。改質後之表面利用接觸 角測試 (contact angle)、衰減式全反射傅立葉轉換紅外線光譜儀 (ATR-FTIR)與化 學分析影像能譜儀 (ESCA)先進行化學定性測試,再進行一系列之生物性測試如 蛋白質吸附、血小板與細胞貼附測試。實驗結果顯示此表面改質方法具有可行性, 在材料吸附性測試中,改質後之矽膠表面吸附量皆有明顯下降。此表面改質方法 對於降低非特異性蛋白質沾黏有顯著性效果,在青光眼引流裝置上應用具有未來 發展性。

Glaucoma, an irreversible damage in eye diseases, usually causes blindness. Several studies have shown that intraocular pressure (IOP) is a major risk factor for optic nerve damage; therefore, the main goal of glaucoma treatment usually focuses on how to reduce IOP sufficiently in order to suppress glaucoma progression. Recently, glaucoma drainage implant (GDI) surgery becomes the main treatment of glaucoma due to its effect on prevention of glaucoma. However, the surgery wound will cause function loss of GDI because the wound healing process will result in protein adsorption, fibroblast adhesion, and proliferation. In this study we modified polydimethylsiloxane (PDMS) surfaces to reduce nonspecific protein adsorption by three hydrophilic polymers. We designed a two steps surface modification method: First, synthesis of silanated hydrophilic polymer and then grafting it onto a PDMS surface. The modified surface was analyzed by surface characterization tests such as contact angle goniometry, attentuated total reflectance Fourier transform infrared spectroscopy (ATR-FTIR) and X-ray photoelectron spectroscopy (XPS). Protein adsorption, platelet adhesion and cell adhesion test were also used to examine the biological effects of modified surfaces. Our results showed that the modification of PDMS surfaces was successful and the modified surfaces significantly reduced protein adsorption, platelet adhesion and cell adhesion.